Axelar AB is a Swedish biotechnology company that focuses
its activities on research related to the insulin-like growth
factor-1 (IGF-1) receptor inhibitors and their applications
in important human diseases, especially cancer.
Axelar’s overall objective is to develop innovative
small-molecule compounds that inhibit the IGF-1 receptor for
treatment of IGF-1 receptor-dependent diseases where a significant
unmet medical need still exists.
Axelar has successfully completed its first Phase I/II clinical
study in advanced-stage cancer patients with solid tumors.
Axelar is now running a randomized Phase II program in patients
suffering from non-small cell lung carcinoma.
April 2, 2013
Preliminary results of a Phase II study indicates that
Axelar’s AXL1717 is efficacious in 2nd line treatment
of patients with lung cancer
January 21, 2013
Investigator sponsored Phase I/II study of AXL1717
in patients with brain tumors started in the US
October 1, 2012
Axelar AB appoints Carl Harald Janson as CEO
June 2, 2012
Axelar AB has presented Phase I/II data of AXL1717
at the American Society of Clinical Oncology (ASCO) Annual
"A novel targeted oral insulin-like growth factor-1
receptor (IGF-1R) inhibitor and its implications for patients
with non-small cell lung cancer (NSCLC): A Phase I clinical